Novartis AG (NVS)
Pre-Market:
| Previous Close | 87.36 |
| Open | 88.43 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1100 |
| Day's Range | 87.62 - 89.64 |
| 52 Week Range | 74.09 - 94.26 |
| Volume | |
| Avg. Volume | 2,362,249 |
| Market Cap | 193.483B |
| Beta (5Y Monthly) | 0.51 |
| PE Ratio (TTM) | 9.23 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.33 (3.81%) |
| Ex-Dividend Date | Mar 08, 2022 |
| 1y Target Est | N/A |
- GlobeNewswire
Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH
First data to be presented as a late-breaker abstract from global pivotal APPLY-PNH trial of investigational oral monotherapy iptacopan in paroxysmal nocturnal hemoglobinaria (PNH), a rare and serious complement-mediated blood disorder New data evaluating the superiority of first-line (1L) Kisqali® plus endocrine therapy vs. combination chemotherapy in pre-menopausal patients with HR+/HER2- metastatic breast cancer with aggressive disease, including patients with visceral disease New analysis fr
- GlobeNewswire
New long-term Leqvio® (inclisiran) data from Novartis show sustained efficacy and safety over four years
Results from ORION-3 open-label trial show twice-yearly* Leqvio®(inclisiran), as a complement to statin therapy, provides effective and sustained reductions in low-density lipoprotein cholesterol (LDL-C) over four years of treatment1,2At any time throughout the trial, approximately 80% of patients reached an LDL-C level of <70mg/dL2Longest Leqvio safety follow-up study to date demonstrates safety-benefit profile is consistent with findings in previous 18-month Phase III trials1-4 LDL-C is one of
- GlobeNewswire
Sandoz announces further investment in key manufacturing facility in Austria, to support increased global demand for essential antibiotics
EUR 50m planned investment to support increased manufacturing capacity for finished dosage form penicillins, the leading class of antibiotics worldwideNew project brings total planned investment into Sandoz antibiotics network across Europe to over EUR 250 millionTechnology upgrades at Kundl site will help to meet increasing global penicillins demand and partially offset impact of high energy costs at unit cost levelSandoz stresses importance of fundamental market reforms to ensure long-term sus
